Ashvattha Therapeutics Announces Investor and Conference Presentations

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing an at-home subcutaneous (subQ) monthly treatment, announced presentations at HC Wainwright Conference, Ophthalmology Futures Retina Forum, and EURETINA, highlighting clinical trial results of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Globally, approximately half (50%) of DME and nAMD patients discon